Sedana Medical AB (FRA:7D2A)

€ 1.066 0.054 (5.34%) Market Cap: 110.49 Mil Enterprise Value: 91.51 Mil PE Ratio: 0 PB Ratio: 1.15 GF Score: 65/100

Q3 2024 Sedana Medical AB (publ) Earnings Call(Q&A) Transcript
Oct 24, 2024

€1.38 (-28.60%)

Earnings
Q2 2024 Sedana Medical AB (publ) Earnings Call Transcript
Jul 23, 2024

€2.03 (-10.20%)

Earnings
Q4 2023 Sedana Medical AB (publ) Earnings Call Transcript
Feb 15, 2024

€1.51 (-10.00%)

Earnings
Q3 2023 Sedana Medical AB (publ) Earnings Call Transcript
Oct 26, 2023

€1.41 (-1.60%)

Earnings
Q2 2023 Sedana Medical AB (publ) Earnings Call Transcript
Jul 21, 2023

€2.02 (+7.57%)

Earnings
Q1 2023 Sedana Medical AB (publ) Earnings Call Transcript
Apr 27, 2023

€2.13 (+7.75%)

Earnings
Q4 2022 Sedana Medical AB (publ) Earnings Call Transcript
Feb 16, 2023

€1.83 (-0.87%)

Earnings
Sedana Medical AB (publ) at Redeye Medtech Seminar (Virtual) Transcript
Oct 26, 2022
Q3 2022 Sedana Medical AB (publ) Earnings Call Transcript
Oct 25, 2022

€2.2 (-2.05%)

Earnings
Q2 2022 Sedana Medical AB (publ) Earnings Call Transcript
Jul 21, 2022

€2.3 (+10.66%)

Earnings
Q1 2022 Sedana Medical AB (publ) Earnings Call Transcript
Apr 28, 2022

€3.21 (-29.55%)

Earnings
Q4 2021 Sedana Medical AB (publ) Earnings Call Transcript
Feb 17, 2022

€6.57 (+1.23%)

Earnings
Q3 2021 Sedana Medical AB (publ) Earnings Call Transcript
Nov 04, 2021

€8.12 (+1.12%)

Earnings
Q2 2021 Sedana Medical AB (publ) Earnings Call Transcript
Aug 19, 2021

€8.23 (+4.18%)

Earnings
Q1 2021 Sedana Medical AB (publ) Earnings Call Transcript
May 06, 2021

€8.34 (+0.60%)

Earnings
Full Year 2020 Sedana Medical AB (publ) Earnings Call Transcript
Feb 25, 2021

€8.71 (-2.65%)

Earnings

Q3 2023 Sedana Medical AB (publ) Earnings Call Transcript

Oct 26, 2023 / 11:30AM GMT

Release Date Price: €1.41 (-1.60%)

Transcript

Johannes Doll;publ;President;CEO

Sedana Medical AB

()-&

Thank you very much. Welcome everybody to our Q3 report. We will follow the same structure today that we always use for these calls. I will kick us off by presenting the performance during the third quarter and the progress we have made against our three strategic priorities.

And Peter Sackey, our Chief Medical Officer, will talk about where we are with our clinical trials in the United States, and our CFO, Johan Spetz, will go a little deeper into the financials. And then we'll wrap it up and we will take time to discuss your questions.

So let's get started on page 3, please. As many of you know, we have the whole company fully focused on three strategic priorities. These priorities are: first, to achieve profitable growth in our current business after having left with the COVID-19 aftermath behind; second, to reach breakeven in our ex-US business during next year already; and third, simultaneously getting closer towards an approval of our inhaled sedation therapy in the United

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.